Growth Metrics

Mesoblast (MESO) Curent Deferred Tax Liability (2017 - 2018)

Mesoblast recorded quarterly Curent Deferred Tax Liability of $19.4 million in Q3 2018, down 3.54% quarter-over-quarter from $20.1 million in Q2 2018, and down 58.25% year-over-year from $46.4 million in Q3 2017.

Mesoblast's Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $19.4 million for Q3 2018.

  • In Q3 2018, Curent Deferred Tax Liability fell 58.25% year-over-year to $19.4 million; the TTM figure through Sep 2018 stood at $19.4 million (down 58.25% YoY), while the FY2018 annual figure was $20.1 million, down 59.27% from the prior year.
  • Curent Deferred Tax Liability came in at $19.4 million for Q3 2018 at Mesoblast, down from $20.1 million in the prior quarter.
  • In the past five years, Curent Deferred Tax Liability ranged from a high of $49.3 million in Q2 2017 to a low of $19.4 million in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Mesoblast 23.40 Bn 23.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2018 19.37 Mn
Sep 30, 2018 19.37 Mn
Jun 30, 2018 20.08 Mn
Jun 30, 2018 20.08 Mn
Mar 31, 2018 21.10 Mn
Mar 31, 2018 21.10 Mn
Dec 31, 2017 23.91 Mn
Dec 31, 2017 23.91 Mn
Sep 30, 2017 46.40 Mn
Sep 30, 2017 46.40 Mn
Jun 30, 2017 49.29 Mn
Jun 30, 2017 49.29 Mn